{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:56:17Z","timestamp":1791356177792,"version":"4.3.1"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn\u2019s disease (CD), is a chronic immune-mediated disorder of rising global prevalence, with newly industrialised nations now entering the phase of most rapid growth. Its therapeutic landscape has transformed since 2020. Three selective interleukin (IL)-23p19 antagonists have been approved for both UC and CD; two sphingosine-1-phosphate receptor modulators and a second-generation Janus kinase (JAK) inhibitor have entered routine practice; subcutaneous formulations have altered delivery; and the first formal head-to-head trials, together with placebo-controlled trials incorporating an active reference arm, have begun to replace indirect comparison with direct evidence. In parallel, the ORAL Surveillance trial prompted a class-wide boxed warning that recalibrated, but did not eliminate, the role of JAK inhibitors. Three further strategies have generated late-phase data: anti-TL1A antibodies, which target a pathway not previously addressed pharmacologically in IBD; the miR-124 enhancer obefazimod; and the oral IL-23 receptor antagonist peptide icotrokinra. Several of these results are available only from conference presentations or company announcements and await peer review. Despite this expansion, induction remission rates remain clustered between roughly 15% and 50%, and endoscopic remission rates lower still. This review synthesises the mechanistic basis, pivotal evidence, comparative effectiveness, safety and regulatory status of approved and investigational therapies for IBD, and how treat-to-target principles, early advanced therapy and emerging biomarkers are reshaping positioning. It also covers two areas comparable reviews omit: acute severe ulcerative colitis, where advanced therapy is least well evidenced, and positioning in newly industrialised nations, where tuberculosis and hepatitis B endemicity and reimbursement, not efficacy alone, often determine the choice of mechanism.<\/jats:p>","DOI":"10.3389\/fphar.2026.1948258","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:47:06Z","timestamp":1791355626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologic and small-molecule therapies for inflammatory bowel disease: mechanisms, comparative evidence and the emerging pipeline"],"prefix":"10.3389","volume":"17","author":[{"given":"Longliang","family":"Wu","sequence":"first","affiliation":[{"name":"Shanghai Longliang Yuanjian Medical Technology Co., Ltd.","place":["Shanghai, China"]},{"name":"Professional Committee of High-Quality Multidisciplinary Team Care for Inflammatory Bowel Disease, Beijing Medical Award Foundation","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjiong","family":"Wu","sequence":"additional","affiliation":[{"name":"Professional Committee of High-Quality Multidisciplinary Team Care for Inflammatory Bowel Disease, Beijing Medical Award Foundation","place":["Beijing, China"]},{"name":"Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","volume-title":"\u201cAbbVie\u201c Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating Risankizumab Subcutaneous Induction in Patients with Crohn\u2019s Disease","year":"2026"},{"key":"B2","volume-title":"Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis","year":""},{"key":"B3","volume-title":"Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database","year":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"910","DOI":"10.14309\/ajg.0000000000002621","article-title":"Efficacy and safety of ustekinumab for ulcerative colitis through 4 years: final results of the UNIFI long-term maintenance study","volume":"119","author":"Afif","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1107976","DOI":"10.3389\/fmicb.2023.1107976","article-title":"Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease","volume":"14","author":"Becker","year":"2023","journal-title":"Front. Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience","volume":"119","author":"Berinstein","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J. Pathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1053\/j.gastro.2026.03.007","article-title":"Interpreting a negative trial in complex perianal Crohn\u2019s disease: the end of allogenic stem cell treatment for fistula patients?","volume":"170","author":"Buskens","year":"2026","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1021\/ml500389m","article-title":"Discovery of APD334: design of a clinical stage functional antagonist of the Sphingosine-1-phosphate-1 receptor","volume":"5","author":"Buzard","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"B13","volume-title":"ZYMFENTRA (Infliximab-dyyb) Injection, for Subcutaneous Use: US Prescribing Information","year":"2023"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with Moderate-to-Severe, active, ulcerative colitis: a phase II study","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/s2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/nejmoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1097\/MIB.0b013e31829936c2","article-title":"Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"19","author":"Costa","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing Infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease","volume":"154","author":"D\u2019Haens","year":"2018","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/nejmoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"jjaf080","DOI":"10.1093\/ecco-jcc\/jjaf080","article-title":"Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis","volume":"19","author":"D'Haens","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/s2468-1253(21)00294-6","article-title":"Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study","volume":"7","author":"Danese","year":"","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/s0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0140-6736(14)61908-5","article-title":"Crohn\u2019s disease management after intestinal resection: a randomised trial","volume":"385","author":"De Cruz","year":"2015","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.gtc.2017.05.013","article-title":"Ustekinumab and Anti-Interleukin-23 agents in Crohn\u2019s disease","volume":"46","author":"Deepak","year":"2017","journal-title":"Gastroenterol. Clin. North Am."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1476213","DOI":"10.3389\/fpubh.2024.1476213","article-title":"Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China","volume":"12","author":"Du","year":"2024","journal-title":"Front. Public Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4049\/jimmunol.153.2.517","article-title":"Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes","volume":"153","author":"Erle","year":"1994","journal-title":"J. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/nejmoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/apt.13398","article-title":"Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn\u2019s disease","volume":"42","author":"Feagan","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/nejmoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/s0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/s0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"jjaf021","DOI":"10.1093\/ecco-jcc\/jjaf021","article-title":"Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review","volume":"19","author":"Gisbert","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/j.gastro.2025.02.033","article-title":"Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn\u2019s disease: results from the phase 3 GRAVITI study","volume":"169","author":"Hart","year":"2025","journal-title":"Gastroenterology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1016\/j.bmc.2014.03.036","article-title":"Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12\/23 inhibitor, APY0201","volume":"22","author":"Hayakawa","year":"2014","journal-title":"Bioorg Med. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"386","DOI":"10.5217\/ir.2020.00080","article-title":"Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)","volume":"19","author":"Hisamatsu","year":"2021","journal-title":"Intest. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1365-2036.2004.01945.x","article-title":"Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery","volume":"19","author":"Ho","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/0092-8674(87)90233-9","article-title":"Integrins: a family of cell surface receptors","volume":"48","author":"Hynes","year":"1987","journal-title":"Cell"},{"key":"B46","volume-title":"Icotrokinra Meets Primary Endpoint of Clinical Response in the Phase 2b ANTHEM-UC Study in Ulcerative Colitis","year":"2025"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/s0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-025-01097-1","article-title":"The global burden of inflammatory bowel disease: from 2025 to 2045","volume":"22","author":"Kaplan","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s40265-025-02202-z","article-title":"Ivarmacitinib sulfate: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/s0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40259-025-00739-9","article-title":"Bidirectional interplay between IBD therapies and the gut microbiota: a pharmacomicrobiomic approach to personalized treatment","volume":"39","author":"Lazarevi\u0107","year":"2025","journal-title":"BioDrugs"},{"key":"B54","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of Anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/nejmoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"Jama"},{"key":"B60","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/s2468-1253(22)00022-x","article-title":"AJM300 (carotegrast methyl), an oral antagonist of \u03b14-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"7","author":"Matsuoka","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B61","volume-title":"Merck\u2019s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-Only Study in Patients with Moderately to Severely Active Ulcerative Colitis","year":"2026"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5217\/ir.2018.16.2.233","article-title":"Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies","volume":"16","author":"Motoya","year":"2018","journal-title":"Intest. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0212989","DOI":"10.1371\/journal.pone.0212989","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/s2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/jgh.14648","article-title":"Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn\u2019s disease in Asia","volume":"34","author":"Ooi","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/s0140-6736(25)00681-6","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn\u2019s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12876-015-0239-9","article-title":"Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes","volume":"15","author":"Pan\u00e9s","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/s0140-6736(16)31203-x","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/s2468-1253(23)00154-1","article-title":"Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting","volume":"8","author":"Parigi","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jgh.14019","article-title":"Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment","volume":"33","author":"Park","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/s2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial","volume":"7","author":"Peyrin-Biroulet","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/nejmoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2391505","DOI":"10.1080\/19490976.2024.2391505","article-title":"Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease","volume":"16","author":"Prins","year":"2024","journal-title":"Gut Microbes"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1053\/j.gastro.2016.02.072","article-title":"Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection","volume":"150","author":"Regueiro","year":"2016","journal-title":"Gastroenterology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"","journal-title":"Lancet"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"","journal-title":"Am. J. Gastroenterol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/nejmoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/nejmoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/nejmoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"","journal-title":"Gastroenterology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"","journal-title":"Gastroenterology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"","journal-title":"Gastroenterology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"","journal-title":"Gastroenterology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of gut-selective pan\u2010Janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme","volume":"14","author":"Sandborn","year":"","journal-title":"J. Crohns Colitis"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/nejmoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S2468-1253(22)00303-X","article-title":"Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial","volume":"8","author":"Sandborn","year":"","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme","volume":"17","author":"Sandborn","year":"","journal-title":"J. Crohns Colitis"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/s0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"","journal-title":"Lancet"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral Janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study","volume":"12","author":"Sands","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/nejmoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"","journal-title":"N. Engl. J. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/nejmoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"","journal-title":"N. Engl. J. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","article-title":"Mongersen (GED-0301) for active Crohn's disease: results of a phase 3 study","volume":"115","author":"Sands","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/s0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/nejmoa2314076","article-title":"Phase 2 trial of Anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ibd\/izae253","article-title":"Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"31","author":"Sands","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/ibd\/izag007","article-title":"Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: final findings from the LUCENT-3 open-label extension study","volume":"32","author":"Sands","year":"2026","journal-title":"Inflamm. Bowel Dis."},{"key":"B107","volume-title":"Duvakitug Phase 2b Maintenance Data in Ulcerative Colitis and Crohn's disease","year":"2026"},{"key":"B108","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/ibd\/izz266","article-title":"The JAK-inhibitor tofacitinib rescues human intestinal epithelial cells and colonoids from cytokine-induced barrier dysfunction","volume":"26","author":"Sayoc-Becerra","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"B109","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1032679","DOI":"10.3389\/fpubh.2022.1032679","article-title":"Landscape and predictions of inflammatory bowel disease in China: China will enter the compounding prevalence stage around 2030","volume":"10","author":"Shao","year":"2022","journal-title":"Front. Public Health"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/ecco-jcc\/jjaa182","article-title":"The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions","volume":"15","author":"Spalinger","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial","volume":"325","author":"Syversen","year":"","journal-title":"JAMA"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"","journal-title":"JAMA"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat. Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","author":"Travis","year":"1996","journal-title":"Gut"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/nejmoa2208450","article-title":"Vedolizumab for the treatment of chronic pouchitis","volume":"388","author":"Travis","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn's disease: a meta-analysis of population-based cohorts","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B122","volume-title":"FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions","year":"2021"},{"key":"B123","unstructured":"FDA approves interchangeable biosimilar for multiple inflammatory diseases\n          \n          \n          2023"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"B125","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","article-title":"Outcomes of Tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"B127","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"","journal-title":"J. Crohns Colitis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/s2468-1253(21)00295-8","article-title":"Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study","volume":"7","author":"Vermeire","year":"","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s2468-1253(23)00208-x","article-title":"Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"B131","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00535-019-01647-w","article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled phase 3 trial with exploratory analyses","volume":"55","author":"Watanabe","year":"2020","journal-title":"J. Gastroenterol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"656452","DOI":"10.3389\/fimmu.2021.656452","article-title":"Targeting immune cell trafficking - insights from research models and implications for future IBD therapy","volume":"12","author":"Wiendl","year":"2021","journal-title":"Front. Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of \u03b14 integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"B136","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/nejmoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1948258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:47:10Z","timestamp":1791355630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1948258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":136,"alternative-id":["10.3389\/fphar.2026.1948258"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1948258","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1948258"}}